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Abstract
This review attempts to move beyond the traditional borders of antiangiogenesis and toward the dynamic, evolving
strategies of vascular modulation. This repositioning entails a two-fold paradigm shift: conceptually, to a view of anti-
angiogenesis as only one part of a larger story, and therapeutically, to approaches which attempt to modulate
tumor blood flow instead of simply inhibiting it. Three vascular modulation strategies—provascular, antivascular,
and redistributive—are presented with representative compounds. These vascular modulation strategies are
described in specific measurable characteristics (blood vessel maturity and type, effect on blood flow, microenviron-
mental target, molecular target, angiogenic biomarker, and imaging biomarkers) that will help define the tumor types
that are more susceptible to a particular vascular modulation strategy thereby guiding therapeutic agent selection
and enabling a personalized medicine approach.
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Introduction
Cancer is a heterogeneous [1] and multifocal disease, not only between
different individuals with neoplasms of the same histologic type but also
often within the same tumor, resulting in unpredictable clinical out-
comes. However, although no two cancers are identical [2], a universal
feature of all solid tumors is their struggle to maintain blood flow to pro-
vide an adequate supply of oxygen and nutrients and to remove toxic
metabolites as well as to serve as a pathway for metastasis. This depen-
dence on a common pathway provides a potential therapeutic opportu-
nity that replaces the tumor with a target of lesser complexity: unlike the
cancer cells, the vascular endothelium is homogenous, genetically stable
[3], and readily accessible through the bloodstream.
The normal adult vasculature is quiescent [4], with endothelial
cells (ECs) dividing approximately every 10 years. In contrast, solid
tumors require constant neovascularization to grow beyond ∼1 mm3
[5] in size; therefore, vascular modulation strategies to enhance, re-
direct, or limit tumor perfusion, provascular (fed), and redistributive
and antivascular (fasted) strategies, respectively, represent promising
anticancer approaches both as single agents and in combination with
other modalities.
In effect, provascular and antivascular approaches can be considered
as two sides of the same coin, exploiting the critical dependency of the
tumor on blood flow as a vulnerability that can be manipulated—in
either direction—to induce antitumor activity alone or in combination
with other therapeutic modalities, such as chemotherapy or radiotherapy.
Redistributive approaches, by contrast, represent an intermediate state
that induces a relative change or reorganization of blood flow within the
tumor through constriction or dilation of sections of the microvascula-
ture, exploiting the heterogeneity of the tumor.
In general terms, from the perspective of a continuum (Figure 1),
and for the convenience of classification, antivascular strategies limit
blood flow and subject the tumor to hypoxia and nutrient stress at
one end of the spectrum, whereas provascular strategies transiently
improve the function of tumor blood vessels at the other. Redistrib-
utive approaches that result in intratumoral variation in blood flow
without necessarily altering the tumor-to-normal tissue perfusion ratio
represent an intermediate position encompassing both extremes. How-
ever, the position of these approaches on the continuum is very much
dependent on the context, so an antivascular agent may become a
provascular agent and vice versa. Cancer is a moving target, and the
applicability and outcome of therapies that affect blood flow are simi-
larly variable in a case-and-tumor-specific manner.
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The field of tumor antiangiogenesis, built on the work of Judah
Folkman [6], and although nascent, has rapidly generated a large body
of multidisciplinary information, encompassing aspects of physics,
mathematics, molecular biology, and engineering. However, rather than
attempting exhaustively to explore and integrate the theoretical or con-
ceptual underpinnings of the field, it is the aim of this review to extract
key translational constituents and, using a top-down, “effect before
cause” approach, synthesize them into six characteristics with potential
clinical application (Table 1). The six characteristics are as follows:
1. Vessel maturity and type
2. Effect on blood flow
3. Microenvironmental target
4. Molecular target
5. Angiogenic biomarkers
6. Imaging biomarkers
These characteristics will be applied in turn to representative ther-
apeutic classes of each of the three vascular modulation strategies. On
the premise that conceptual clarity is inversely proportional to bio-
logic complexity, we have focused on key interactions rather than
incorporating a vast amount of information.
This review attempts to move beyond the traditional borders of
antiangiogenesis and toward the dynamic, evolving strategies of vascu-
lar modulation. This repositioning entails a two-fold paradigm shift:
conceptually, to a view of antiangiogenesis (and vascular disruption)
as only one part of a larger story, and therapeutically, to approaches that
attempt to modulate tumor blood flow instead of simply inhibiting it.
The unpredictable element, contributing to the variability of the
response, is nitric oxide (NO), the reappearing multifacted regulator
that, depending on the context, can influence the therapeutic outcome
positively or negatively. Its pleiotropic role in vascular modulation and
its important relationship to the smooth muscle containing pericyte
(PC) that coats the ECs in the microvasculature will be emphasized
throughout this review.
Antivascular Strategies
The old dictum “feed a cold, starve a fever” can be less succinctly
restated in oncologic terms as “feed the normal tissue, starve a tumor.”
The requirements of this modified dictum are met by the vascular
targeting agents, namely, the 1) the vascular disruptive agents (VDAs)
that occlude preexisting vessels, 2) the anti-vascular endothelial
growth factors (VEGFs) that prevent new blood vessel formation, 3)
the NO synthase (NOS) inhibitors such as L-NNA and depending
on the context, and 4) the vasodilators such as NO, which can reduce
tumor perfusion through diversion of blood flow through the steal
phenomenon [7].
Vascular Disruptive Agents
The vessel microenvironment. Fully functional blood vessels are
composed of ECs and perivascular mural cells; for example, PCs
and vascular smooth muscle cells (vSMCs) [8]. Without PCs, vessels
are immature and require VEGF stimulation for continued survival.
With PCs, ECs lose their dependence on VEGF, and blood vessels are
characterized by a nonangiogenic, mature, stable phenotype [9]. Ag-
gressive tumor angiogenesis is attributed to abnormal PC production
of VEGF especially under hypoxia resulting in EC proliferation [10].
Essentially, the two cell types exhibit a marked functional interdepen-
dence and act as a structural unit to promote their mutual survival [11].
Figure 1. Vascular modulation continuum.
Table 1. Vascular Modifying Strategies.
Strategy Antivascular Redistributive Provascular
Therapy Class Vascular Disrupting
Agents
Antiangiogenic Anti-VEGF
Antibodies, VEGFR
Kinase Inhibitors
NOS Inhibitors NO Donors
Compound Example Combretastatin A-4 Bevacizumab (Avastin) L-NNA RRx-001 Nitroglycerin
1 Vessel maturity and type Immature but established Immature and newly formed Mature Mature Mature
2 Effect on blood flow Decreased Decreased Decreased Redistributed Increased/decreased (variable)
3 Microenvironmental target ECs ECs Microvessels Hemoglobin PCs
4 Molecular target Tubulin Circulating VEGF eNOS NO Guanylate cyclase
5 Angiogenic biomarker α-SMA eNOS MVD HTN, eNOS, α-SMA eNOS, α-SMA α-SMA, eNOS CD31, CD34 Blood pressure, α-SMA eNOS
6 Imaging modality DCE-MRI DCE-MRI CEUS, DCE-MRI or DCE-CT DCE-MRI, CEUS DCE-MRI, CEUS
HTN indicates hypertension.
134 Vascular Modulation as an Anticancer Therapy Oronsky et al. Translational Oncology Vol. 5, No. 3, 2012
PCs are solitary vSMC-like cells [12] associated with the smallest
diameter blood vessels, that is, arterioles, capillaries, and venules,
whereas larger vessels such as arteries and veins are surrounded by
concentric layers of vSMCs. Blood vessels initially form as endothelial
tubes without PC contact. ECs secrete platelet-derived growth factor-
BB leading to PC proliferation and migration [13] and the sub-
sequent coverage of ECs by PCs results in vessels with a more
mature and stable phenotype [14]. Conversely, tumor blood vessels
are often characterized by a high microvessel density (MVD), a low
ratio of PCs [15] to ECs, and/or an abnormally loose association [16],
leading to vessel destabilization [17], abnormal morphogenesis [18],
and impaired vasoregulation.
PCs possess contractile proteins [19] such as α smooth muscle actin
(α-SMA), tropomyosin, and myosin. Similar to the smooth muscle cells
of larger vessels, they can therefore regulate vascular diameter and capil-
lary blood flow in response to vasoactive substances like prostacyclin,
endothelin 1, and angiotensin II. NO, which is produced by ECs, medi-
ates PC relaxation through guanylyl cyclase that is expressed in PCs [20].
Elevated levels of carbon dioxide can also induce relaxation, whereas
hyperoxia increases PC contraction [21], thereby restricting blood flow.
The presence and distribution of PCs in the tumor can be determined
by immunohistochemical staining for α-SMA [22].
VDA: An overview of combretastatin A4P (Zybrestat). Combre-
tastatin A4 phosphate (CA4P), the most advanced small-molecule
VDA in clinical development and with some structural similarity
to colchicine [23], binds the colchicine binding site on tubulin and
disrupts the cytoskeleton of actively proliferating ECs [24] in PC-
depleted tumor vessels, inhibiting their mitotic division and causing
a reversible shutdown of tumor blood flow. However, mature PC-
stabilized vessels are relatively resistant to CA4P [25]. The activity
of the VDAs is typically confined to the hypoxic, VEGF-dependent
vessels in the center of the tumor [26] while sparing the more mature
and stable vasculature in the periphery. Recently, Zybrestat became
available for compassionate use in patients being treated for anaplastic
thyroid cancer in Canada and Europe. The vascular disrupting char-
acteristics of Zybrestat are also being developed to target polypoidal
choroidal vasculopathy.
Resistance to CA4P is also correlated with tumor overexpression of
inducible NOS. Tozer et al. [27] and Davis et al. [28] have demon-
strated enhanced efficacy of CA4P in previously unresponsive SaS
tumors (increased NOS activity) in the presence of the NOS inhibitor,
L-NNA, by suppression of the proangiogenic and vasodilatory effects of
NO. Therefore, endothelial NOS (eNOS) expression in tumors, deter-
mined immunohistochemically, has a potential role as a surrogate pre-
dictor of activity in conjunction with α-SMA and VEGF. It is therefore
possible that CA4P monotherapy demonstrated a significant survival
benefit [29] in thyroid anaplastic carcinomas [30] that are characterized
histologically by the presence of neovessels lacking PC support.
A phase 1 study of CA4P in combination with the anti-VEGF
antibody, bevacizumab, showed statistically significant but reversible
reductions in tumor perfusion/permeability by dynamic contrast-
enhanced magnetic resonance imaging (DCE-MRI) with CA4P
alone that were sustained after bevacizumab [31]. A potential ratio-
nale for this observation is that addition of the anti-VEGF antibody
resulted in devascularization of the residual tumor rim. In addition,
the therapeutic enhancement could be attributed to the prevention of
regrowth of the neovasculature and the inhibition of VEGF-induced
release of NO from ECs.
Potential biomarker signatures predictive of CA4P therapeutic
outcome and combination strategies. Tumor response to treatment
is typically assessed by measuring tumor size with axial computed
tomography (CT) or MRI, following the Response Evaluation Criteria
in Solid Tumor guidelines. However, because combretastatin rarely re-
sults in immediate tumor shrinkage [32], anatomy-based imaging tech-
niques may at best be a lagging indicator of the effectiveness of the
VDA treatment regimen. T1-weighted DCE-MRI is a convenient
modality that has been used in clinical trials with CA4P to track a bolus
of Gd contrast agent for tumor perfusion measurements and vascular
permeability characterization [33]. Monitoring tumor perfusion may
be a way to predict tumor response early in the course and be used
as a predictor of activity and be used as a guide to the optimal timing
for the administration of combination therapy. A potential biomarker
signature predictive of CA4P therapeutic outcome across multiple can-
cer types and subcategories of disease may be a low expression of eNOS,
α-SMA, and VEGF, a high MVD, and a posttreatment reduction
(within 24 hours) of tumor perfusion measured by DCE-MRI.
In addition to conventional chemotherapy, radiotherapy, and anti-
angiogenic therapy, VDAs could also be effectively combined with NO
inhibitors and/or a hypoxia-selective agent like mitomycin C on the
premise that the VDA will result in vessel shutdown and accentuate
the hypoxia in the center of the tumor, thereby potentiating the activity
of mitomycin C.
Antiangiogenic Agents: Bevacizumab (Avastin)
VEGF, bevacizumab, and the NO connection. A representative
anti-VEGF inhibitor is a humanized monoclonal antibody (bevacizumab
[Avastin]) approved by the US Food and Drug Administration as a
first-line treatment for metastatic colorectal cancer in combination with
5-fluorouracil. The multitargeted tyrosine kinase inhibitors, sunitinib
(Sutent) and sorafenib (Nexavar), which target VEGF in addition to
other receptor tyrosine kinases, and the mTor inhibitors, temsirolimus
(Torisel) and everolimus (Afinitor), which indirectly affect VEGF syn-
thesis [34] are outside the scope of this review.
The VEGF family of growth factors consists in humans of five
separate gene products, termed VEGF-A (or VEGF), VEGF-B,
VEGF-C, VEGF-D, and placental growth factor, with roles in em-
bryogenesis, development, and tissue remodeling. VEGF-A is gen-
erated in almost all cells, including ECs, under unfavorable stress
conditions such as hypoxia and is a key driver of aberrant angio-
genesis in tissues undergoing growth or remodeling [35], including
cancers through binding to two tyrosine kinase receptors, VEGFR-1
(flt-1) and VEGFR-2 (flk-1/KDR), on the surface of ECs [36].
VEGF is secreted by PCs in the microvasculature especially under
hypoxic conditions, establishing a paracrine loop of EC vasoprolifer-
ation [37]. Endothelial survival in newly formed vessels is VEGF-
dependent and withdrawal of VEGF in vessels lacking PCs [38] results
in selective apoptosis.
In addition, VEGF generates vasodilation and promotes increased
vascular permeability [39], leading to the local extravasation of plasma
proteins and matrix components that facilitate endothelial migration
[40]. VEGF expression is regulated by several transcription factors,
including hypoxia-inducible factor 1α, and mediators such as NO
released by NOS.
VEGF-induced vasodilation and its effect on vascular permeability
are dependent, at least in part, on the downstream effects of NO. The
regulation is reciprocal: NO can upregulate VEGF by enhancing
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hypoxia-inducible factor 1 activity [41]. The development of hyper-
tension, occurring in 24% [42] of bevacizumab-treated patients,
possibly due to the inhibition of NO synthesis, is associated with
improved outcomes [43] and may serve as a correlate of efficacy.
Vascular normalization and VEGF inhibitors: Is bevacizumab
antivascular or provascular?. Jain et al. [44] have coined the term
vascular normalization to describe the pruning of immature or nascent
vessels that lack a PC coating and the relative enrichment for PC-coated
mature vessels. Immature vessels are hyperpermeable and tortuous;
mature vessels are not. The prevention of neovasculogenesis and resul-
tant decrease in interstitial pressure results in improved perfusion and
oxygenation [45], paradoxically turning an antivascular agent into a
provascular one.
However, in breast and colorectal studies, a consistently increased
dose response was not observed in combination with standard che-
motherapy (irinotecan/5-fluorouracil/leucovorin). In fact, treatment
with 5 mg/kg bevacizumab seemed to be more effective than the
10-mg/kg dose in the colorectal study. This led at least one author
[46] to speculate, somewhat paradoxically, that a relatively low-dose
bevacizumab may have resulted in reduced intratumoral pressure and
improved delivery of chemotherapy, whereas higher doses may have
caused vascular collapse inside the tumor, thereby limiting delivery of
chemotherapy and reducing the overall antitumor activity.
Biomarkers and imaging modalities. Bevacizumab has a clear
biologic effect that depends on binding VEGF, thus blocking VEGF
signaling. However, measurement of baseline levels of VEGF expres-
sion in metastatic colorectal, non–small cell lung, and renal cell
cancers has failed to predict benefit, possibly because, although VEGF
may be the most important proangiogenic factor in early-stage disease, in
later-stage disease, compensatory responses come into effect, which ex-
ploit multiple pathways rendering the VEGF response less critical [47].
Hypertension may serve as a surrogate marker for anti-VEGF
activity, but the association of bevacizumab with congestive heart
failure [48] may exclude the treatment of patients with preexisting
cardiac disease. In suitable patients, a high expression of eNOS in
the tumor could be exploited as a surrogate biomarker of VEGF-
dependent tumor growth because VEGF reciprocally upregulates NO.
DCE-MRI can be used to study changes in K trans, a measure of
permeability and perfusion. Significant lowering of this parameter
after drug administration would reflect a decrease in tumor vas-
cular permeability and/or flow and would be consistent with
“vascular normalization.”
A relative increase in the immunohistochemical staining intensity of
α-SMA over time would also be consistent with vascular normalization.
Potential combination therapies. Acting as a provascular agent at
low doses, bevacizumab has potential as a chemoradiosensitizer,
increasing oxygen and drug delivery. Results of a small phase 1 to 2 trial
in locally advanced rectal cancer with bevacizumab and erlotinib in
combination with continuously infused 5-fluorouracil and radiotherapy
demonstrated a pathologic complete response in 7 (47%) of 15 patients
who completed study therapy, and no local recurrences were observed
after a median follow-up of 7 months [49].
As an antivascular agent at high doses, bevacizumab could increase
the degree and severity of hypoxia in tumors. Therefore, it would make
sense to combine bevacizumab with preadministered hypoxia-activated
agents like mitomycin C. In such a combination, the hypoxia-activated
compound could exploit bevacizumab-induced increased hypoxic frac-
tion to selectively kill cancer cells with decreased systemic toxicity.
NOS Inhibitors—L-NNA
eNOS, α-SMA, and NO. NO is generated endogenously by NOS
in mammals from the oxidation of L-arginine to L-citrulline. NOS can
be categorized into three isoforms: neuronal (nNOS or NOS-1; an
“NO brainer”), cytokine-inducible (iNOS or NOS-2), and endothelial
(eNOS or NOS-3) [50]. eNOS is regulated bymultiple interdependent
control mechanisms and signaling pathways [51] including VEGF. The
activity of the enzyme directly promotes the relaxation of vSMCs and
PCs through stimulation of NO generation, leading to a reduction in
blood pressure.
The ability of NO generated by eNOS to modify tumoral hemo-
dynamics depends on the presence of smooth muscle–containing
PCs in the microvasculature. Vessels devoid of α-SMA are incapable
of active vasoconstriction/vasodilation [52].
The close association between eNOS and smooth muscle provides
an anatomic basis for reciprocal regulation in the presence of agonists/
antagonists. eNOS has been reported to associate with globular actin,
and this association increases the activity of the enzyme. In a study
in cultured human umbilical vein ECs, eNOS agonists adenosine,
histamine, salbutamol, and thrombin all caused an increase in associ-
ation between eNOS and globular actin [53].
NO inhibition as an antivascular strategy. The inhibition of NO
synthesis has tumor antivascular activity that can be attributed to the
involvement of NO in tumor angiogenesis and the maintenance of
vasodilator tone of tumor blood vessels. A clinical phase 1 dose esca-
lation study demonstrated that a single intravenous dose of L-NNA, a
nonspecific NOS inhibitor with slightly greater selectivity for eNOS,
decreased vascular blood volume by 40%, as measured by dynamic
contrast CT, in non–small cell lung tumors, an effect that is sustained
24 hours after treatment [54].
The disruption of the tumor vasculature was preceded by a mild
increase in blood pressure that returned to baseline in 3 hours [55].
The investigators attributed this discrepancy between the duration of
the antiangiogenic and the cardiovascular effects (24 vs 3 hours) to a dif-
ferential dependence on NO in healthy tissue compared with cancerous
tissue [55]. Unlike the cardiovascular system, which is subjected to
tightly regulated homeostatic controls [55], the patency of vessels within
these tumors is maintained by increased expression of NO. Therefore,
the consequence of NO inhibition was a conversion of net vasodilation
to frank vasoconstriction with a catastrophic collapse of blood flow.
Biomarkers and imaging modalities. Implicit in this assumption
about the differential effect of NO is a diffuse expression of SMA in
the tumor. The reversal from dilation to constriction implies the pres-
ence of PCs in the tumor endothelium, which can dilate or constrict
in the presence or absence of NO. Tumors that express a high basal
level of eNOS and α-SMA may be particularly susceptible to the
effects of treatment with NO inhibitors. Doppler ultrasound with in-
travenously injected gas- or air-containing microbubbles (contrast-
enhanced ultrasound or CEUS) could also be used as an imaging
biomarker to quantify tissue perfusion. CEUS presents several advan-
tages over other imaging techniques such as DCE-MRI and CT, in-
cluding the use of microbubbles as blood pool agents, portability,
availability, and absence of risk of nephrotoxicity and exposure to
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radiation. Owing to their size, microbubbles remain strictly intravascular
where they can be detected with high sensitivity and specificity.
Potential combination therapies. As an antivascular agent that
could increase the degree and severity of hypoxia in tumors, these
observations suggest some specific combination therapies. In a simi-
lar combination to high-dose bevacizumab with CA4P, L-NNA
could be combined with preadministered hypoxia-activated agents
like mitomycin C.
Systemic Vasodilators and Vasoconstrictors
Adjustments to systemic changes must take place at the local
tumor level. The administration of a vasodilator or a vasoconstrictor
will result in decreased tumor perfusion if PCs that can respond to
vasoactive stimuli are largely absent and the host and vascular beds
are in parallel rather than in series [56]. However, because of the
nonhomogenous distribution of vascular beds in most tumors, the
net response to changes in systemic blood pressure is highly unpredict-
able and heterogeneous.
For example, the use of vasoconstrictors such as endothelin and
angiotensin II [57] can lead to either improved blood flow to the
tumor from unequal vasoconstriction of host vessels or decreased
tumor blood flow, if the tumor endothelium expresses receptors that
mediate vasoconstriction.
Similarly, vasodilators like NO donors can either mediate in-
creased or decreased tumor perfusion, secondary to microvessel relax-
ation or to vascular steal, an effect that is due to a greater reduction of
the total resistance of the peripheral circulation diverting blood away
from the tumor. NO-based therapies, in particular, will be discussed
in greater detail in the next paragraphs under provascular strategies.
Redistributive Strategies
Provascular and antivascular strategies involve a general or global
change in perfusion to the tumor. Redistributive strategies, by con-
trast, induce local hemodynamic variations at the microregional level
of the tumor, shifting blood flow and oxygenation into reconfigured
zones, without necessarily influencing global perfusion. This hemo-
dynamic reapportionment has the potential to minimize systemic ef-
fects and thereby improve the therapeutic index both as monotherapy
and in combination because perfusion in the rest of the organism is
differentially less affected.
By this definition, the administration of L-NNA to patients with
non–small cell lung carcinoma represents a hybrid of antivascular and
redistributive strategies because a global decrease in tumor perfusion
(antivascular) was achieved with minimal effects on systemic hemo-
dynamics (redistributive).
A key factor governing the sensitivity of the vasculature to thera-
peutic intervention is the abundance and distribution of α-SMA.
Given the phenotypic heterogeneity of cancer, the effects of L-NNA
could vary in different tumor types and even in individual patients.
If the distribution of PCs in the tumor is focal, then the overall effect
of L-NNA–induced NO inhibition would be antivascular through
vasoconstriction in that zone. If the PCs are diffusely present in the
tumor, then the net effect might be redistribution through siphoning
of blood from PC-constricted microvessels to adjacent nonconstricted
microvessels without PCs. Overall, blood flow and oxygenation are
gerrymandered from one area of the tumor to another, but quantitative
tumor perfusion may remain relatively stable.
The immature, unstable vessels in the tumor lacking PCs are
prone to acute or transient hypoxia, resulting from intermittent
closure. A redistributive agent that redirects blood flow in this way
could lead to changes in the acute hypoxic pattern owing to the
opening and closure of different blood vessels.
Redistribution is a novel and unique strategy. The ability to test this
hypothesis has been hampered by the lack of chemical agents; however,
we now have access to such a molecule in RRx-001.
RRx-001
RRx-001, an example of a small molecule parenterally dosed redis-
tributive agent, is in phase 1 clinical evaluation in patients with ad-
vanced solid tumors and lymphomas [58]. The compound, sourced
from the defense industry, and modified from a component in rocket
fuel, is characterized by a pharmacologically unprecedented chemical
structure, a pernitro-substituted strained four-member ring and pos-
sesses a novel mechanism of action. The molecule consists of two
functional ends: a highly electrophilic center that rapidly reacts with
hemoglobin and specific soluble thiols, depleting glutathione and a
latent NO-donating moiety that is activated subsequent to reduc-
tion of the nitro groups on the four-member ring [59]. The cova-
lent modification of hemoglobin through binding of RRx-001 to the
β-Cys93 residue changes the oxygen affinity (lowering P50) and
increases the capacity of the red blood cells to generate NO from
nitrite (NO2
−) [60].
Paradoxically, for a putative NO donor, RRx-001 administration
in dogs led to a transient and mild increase in blood pressure, whereas
mouse SCCVII and RIF-1 syngeneic tumors responded with a diffuse
sustained vasoconstriction that resulted in blood flow redistribution
for up to 72 hours and significant tumor cytotoxicity with minimal
systemic adverse effects at therapeutic doses, both as monotherapy
and in combination with radiotherapy (XRT).
The rationale for this perfusion redistribution is that murine
squamous cell carcinoma cell line (SCCVII) and murine radiation-
induced fibrosarcoma cell line (RIF-1) syngeneic murine tumors
stain diffusely for α-SMA vessels; RRx-001 led to an acute change
in blood flow and hypoxia distribution owing to the opening of im-
mature (PC-poor) vessels and the closure of mature (PC-rich) vessels
(RadioRx, unpublished observations, 2012). In the context of a
glioma xenograft, U87, where the distribution of α-SMA was sparsely
focal, RRx-001 had an antivascular, rather than a redistributive, ef-
fect, resulting in transient vasoconstriction and increased hypoxia, as
assessed by staining with the oxygen dependent probe, pimonidazole.
In effect, RRx-001, as a mixed NO inhibitor, dispenses NO in to the
circulation but results in rapid NO indirect scavenging also through
superoxide anion generation from glutathione depletion. The bio-
character of RRx-001 can be shifted from single-agent NO antagonist to
NO superagonist when combined with nitrite, which undergoes an ac-
celerated catalytic reduction to NO by RRx-001–modified hemoglobin.
A treatment regimen alternating between single-agent RRx-001
and a combination of RRx-001 with sodium nitrite or XRT, to stress
the tumor with cyclical fluctuations in perfusion and reactive nitro-
gen species may prevent tumor adaptation and escape mechanisms.
This approach may be especially useful when combined with XRT
in particular owing to dynamic changes in tumor oxygenation and
nitrosation that will enhance radiosensitization. To support this
hypothesis, a biomarker “portfolio” predictive of activity will be eval-
uated in the clinic and includes eNOS, α-SMA, CD31, CD34,
thrombospondin-1, DCE-MRI, and CEUS. On the basis of observed
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preclinical radiosensitization, a phase 2 study is planned with XRT in
selected patients with susceptible tumor types based on the analysis of
this biomarker portfolio in phase 1.
Provascular Strategy—Nitric Oxide
The term provascular, introduced by Sonveaux et al. [61], refers col-
lectively to agents that exploit the differential reactivity of mature
tumor blood vessels to increase tumor perfusion and oxygenation
temporarily. If the benefits of antiangiogenesis can be understood
simplistically in oxygen deficiency and nutrient deprivation to the
tumor leading to cytostasis, the advantages of a provascular strategy
from improved oxygenation and drug delivery are less apparent and
seemingly outweighed by potential stimulation of tumor growth
associated with increased perfusion.
Pharmacokinetic modulation to increase tumor blood flow has
been investigated with several agents including NO [62]. The utility
of NO as a provascular agent depends on the functional role of PCs
in the tumor vasculature; transient relaxation of these cells may tem-
porarily increase blood flow. Conversely, however, because normal
tissue blood vessels are highly sensitive to vasodilation, and tumor
perfusion pressures are influenced by systemic perfusion pressures,
a reduction in tumor blood supply can also occur through vascular
steal. Therefore, selective tumor vascular reactivity is dependent on
local delivery of NO to the tumor from, for example, local low-dose
radiation, which induces a dose-dependent up-regulation of eNOS
[63] or an NO donor like RRx-001, which functionalizes hemoglo-
bin and, in combination with nitrite, converts red blood cells into
circulating bioreactors that preferentially deliver NO on-demand
under hypoxia.
However, although it is extremely attractive to “starve” a tumor
into nongrowth or growth at submaximal rates in principle, anti-
angiogenesis has been disappointing in practice. Because hypoxia is
the major driver of malignant progression, angiogenesis, and treat-
ment resistance, the benefits to the patient and the clinician of tumor
reoxygenation and a reduction in the hypoxic fraction may actually
favor a provascular rather than an antivascular approach. The pro-
vascular paradox is that normalization of the tumor vasculature can
lead to improved blood flow, making the distinction between pro-
vascular and antivascular agents somewhat artificial because both
strategies are contextually morphable depending on the dose and
the tumor type. According to Sonveaux et al., the real benefit of a
selective provascular approach is that, because tumor tissues are more
hypoxic and less perfused than normal tissues, the impact on the
tumor of even a small enhancement of oxygenation and blood flow
is substantial, resulting in chemoradiosensitization.
In addition, when the tumor vasculature is PC-poor, systemic de-
livery of a vasoconstrictor, such as angiotensin II, rather than a vaso-
dilator, will indirectly increase blood flow to the tumor, through an
anti–steal effect involving vasoconstriction of normal, but not tumor,
blood vessels. Important systemic and biopsy biomarkers could include
blood pressure (because a precipitous decrease would herald a decrease
in tumor perfusion through steal) and eNOS and α-SMA, respectively.
Conclusions
It has often been stated that cancer is not one disease but more than a
hundred different diseases that present variable clinical courses and
treatment challenges [64]. The attraction of vascular modulation is
that it addresses the therapeutic disadvantages of cancer heterogene-
ity: the common denominator of all tumors regardless of histologic
features, biologic profile, and imaging characteristics is a complete
reliance on blood flow to maintain growth, progression, and metas-
tases. This reliance is the Achilles’ heel of cancer, and the ability to
manipulate and exploit it using vasoactive and antivascular agents,
both separately and in combination, as a means of destroying the
tumor itself, is the Holy Grail in oncology.
Although deceptively simple, the tumor vasculature is no different
from the tumor in its heterogeneity, and the kaleidoscopic interplay
between the components of the microenvironment—the ECs, the
smooth muscle—containing PCs and endogenous angiogenic factors,
such as VEGF and NO, which influence the treatment outcome.
From an understanding of the complexities of the tumor, vasculature
and microenvironment have emerged a continuum of strategies, from
antivascular to provascular, to target blood flow as a whole and not just
the epithelial component of the neovasculature. Moreover, the absence
of a single therapeutic target for the tumor vasculature has led to an
emphasis on rational combinations of therapies chosen on the basis
of particular “biomarker signatures” predictive of microenvironmental
conduciveness in individual tumors.
The continuum presented in the introduction is, of course, an
oversimplified construct, but it provides a conceptual taxonomy for
the different strategies in this review. None of the strategies are in-
tentionally presented as “better” or more “desirable” than another. In
fact, depending on the context, they are relatively interchangeable.
The continuum is a static representation, and the therapies that are
identified as belonging to discrete categories—antivascular, redistrib-
utive, or provascular—are capable of dynamically switching their
effect on blood flow, mirroring the adaptive response of the tumor
itself to vasoactive challenges. This therapeutic fickleness can be ma-
nipulated to fine-tune the vascular response through dose adjustment
or addition of a second modality.
The mismatch between static, linear treatment regimens with fixed
maximum tolerated doses (MTDs) and schedules and the dynamic
evolutive responses of tumor cells to chemotherapy and radiotherapy in
some cancers inevitably results in the development of therapeutic re-
sistance. Moreover, treatment failure is typically determined post hoc
with static imaging instead of ad hoc with dynamic MRI or CEUS,
exacerbating the disconnect.
In contrast to this conventional Response Evaluation Criteria in
Solid Tumor and MTD-based clinical methodology, vascular modu-
lation strategies have the potential to provide a flexible platform for
iterative therapeutic tailoring based on rapid feedback: treatment can
be continuously adapted to real-time changes in tumor blood flow
with dynamic CEUS and/or DCE-MRI.
In this therapeutic serve-and-volley between provascular and anti-
vascular approaches, the clinician theoretically has the advantage be-
cause, with every phenotypic adaptation, the tumor pays an efficiency
price, diverting energy and resources from invasion to evasion, thereby
rendering it more vulnerable to subsequent therapeutic attacks.
Thus, in conclusion, the prospect of vascular modulation strategies
that, through biomarker identification and serial imaging techniques,
can become as adaptive and dynamic as the tumor itself offers new hope
and new opportunities for improving the care of cancer patients.
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